Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acorda Therapeutics, a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders, has appointed John Kelley, president and COO of The Medicines Company, to its board of directors.
Subscribe to our email newsletter
Prior to joining The Medicines Company, Mr Kelley held several senior management positions at Aventis Pharmaceuticals, most recently as senior vice president of global marketing and medical, where he was responsible for worldwide brand management of its core strategic brands and also managed strategic alliances with its partner companies.
Mr Kelley has received a BA from Wilkes University and an MBA from Rockhurst University.
Ron Cohen, president and CEO of Acorda Therapeutics, said: “John brings to Acorda outstanding experience and achievements in pharmaceutical commercialization and corporate strategy. We look forward to working with him as we advance toward the potential approval and launch of Fampridine-SR, our lead product for multiple sclerosis.”